Neuroendocrine Neoplasms of the Colon: Reading the Two Axes

A biopsy that forces the question

A core biopsy arrives from a right colon mass. Under the scope you see organoid nests and trabeculae, uniform cells with stippled "salt-and-pepper" chromatin — unmistakably neuroendocrine. Then the Ki-67 comes back at 28%. So where does this tumor sit? Is it a high-grade well-differentiated NET, or is it a neuroendocrine carcinoma? That question isn't academic. The two answers point to different biology, different molecular expectations, and a different clinical trajectory — and the proliferation index alone won't settle it.

This is the central puzzle of colorectal neuroendocrine neoplasms (NENs), and it's worth walking through carefully.

What it is, and where it sits

In the WHO 5th edition scheme, neuroendocrine neoplasms of the digestive system are recognized entities, distinct from conventional adenocarcinoma [1]. The category has an internal architecture built on two independent axes, and confusing them is the most common conceptual error I see in trainees.

The first axis is differentiation — a qualitative, morphology-driven judgment. Well-differentiated tumors are called neuroendocrine tumors (NETs); poorly differentiated ones are neuroendocrine carcinomas (NECs) [1]. The second axis is grade, a quantitative measure of proliferation. That's the Ki-67 and mitotic count.

Here's the point that resolves the opening biopsy: a NET can be high-grade (G3) and still be a NET. It is not automatically a NEC just because Ki-67 crosses some threshold. NEC is a diagnosis rooted in poorly differentiated morphology, not in the proliferation number alone [1]. Sitting alongside these is the mixed neuroendocrine–non-neuroendocrine neoplasm (MiNEN), in which a neuroendocrine component coexists with a non-neuroendocrine component — typically adenocarcinoma — each comprising at least 30% of the tumor [1].

How a pathologist recognizes it

The diagnostic order matters, and it runs morphology → immunohistochemistry → molecular.

Morphology first. Neuroendocrine differentiation announces itself architecturally: organoid nests, trabeculae, rosettes, and that characteristic finely granular chromatin. Well-differentiated NETs show this organoid pattern with relatively monotonous cytology. NECs look different — sheets of poorly differentiated cells, often with the small-cell or large-cell appearance familiar from pulmonary NEC, brisk mitoses, and necrosis [1].

Immunohistochemistry confirms. The neuroendocrine phenotype is verified with synaptophysin and chromogranin, and increasingly with the nuclear transcription factor INSM1 [1]. A Ki-67 stain is then run to establish the proliferation index, and mitoses are counted. IHC confirms lineage; it does not, by itself, assign differentiation — that's still a morphologic call.

Molecular last, and confirmatory. Poorly differentiated colorectal NECs share the molecular profile of high-grade NECs elsewhere, with recurrent TP53 and RB1 alterations [1]. That signature can support a NEC diagnosis when the morphologic distinction from a G3 NET is genuinely difficult — precisely the situation posed by our 28% case.

Grading and classification

Well-differentiated NETs are graded G1, G2, or G3 using Ki-67 and mitotic count [1]. NEC is, by definition, a high-grade tumor and is not subdivided along the same NET grading axis [1]. MiNEN is classified by the proportions of its components, each of which must reach the 30% threshold to qualify [1]. Notably, the NET grading axis parallels what's used for gastroenteropancreatic and pancreatic NETs — a shared framework that makes the colorectal grading intuitive if you already work with pancreatic cases [1].

Why the distinction matters clinically

This is where getting the classification right earns its keep.

Differentiation and grade carry different clinical meaning, and treating them as interchangeable can misdirect care. A well-differentiated G3 NET and a poorly differentiated NEC may share a similar Ki-67, yet they are biologically distinct diseases — different natural histories, different molecular underpinnings, and eligibility for different therapeutic classes rather than any single regimen [1]. Misfiling a G3 NET as a NEC, or the reverse, can therefore steer a patient toward an entirely inappropriate line of management. That's not a subtle error; it's a categorical one.

The MiNEN designation guards against a related trap in both directions. Under-calling is the more insidious problem: a small nest of scattered neuroendocrine cells within an adenocarcinoma does not make a MiNEN. Unless the neuroendocrine component reaches that 30% bar, the tumor stays an adenocarcinoma with neuroendocrine differentiation [1]. Over-call it and you've relabeled a common cancer as a rare mixed entity. Under-recognize a genuine high-grade neuroendocrine component that does meet the threshold, and you've missed a clinically consequential population of tumor cells that behaves aggressively. The 30% rule exists precisely to impose discipline here, and I'd argue it's the single most misapplied number in this part of the classification.

The grading axis within NETs also carries a prognostic gradient — the ordering from G1 through G3 reflects increasing proliferative activity and, correspondingly, more aggressive behavior [1]. That gradient is the reason we count carefully rather than eyeball a rough estimate; the difference between a G1 and a G2 hinges on the index, and the index can move management.

A note on where this is heading

Return to the 28% biopsy. The morphology — organoid, monotonous, no sheeting or necrosis — argues for a G3 NET, and if TP53 and RB1 come back intact, that reading holds. The molecular data increasingly do this work at the margins, helping separate the well-differentiated high-grade tumor from true NEC when the H&E alone leaves room for doubt [1]. It's a genuinely evolving space, and the boundary between G3 NET and NEC is one worth watching as the molecular evidence accumulates.

This article is educational and describes how these diagnoses are made; it is not treatment advice.

References

1. WHO Classification of Tumours Editorial Board. Digestive System Tumours, 5th ed. Lyon: IARC; 2019. ISBN 978-92-832-4499-8.